AZNAstraZenecaRunning, no new patients
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
Muscle Invasive Bladder Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,063 (final count)
- Started
- Nov 16, 2018
- Main results expected
- Apr 29, 2024
- Fully finished
- Nov 8, 2027
- Results posted
- Jul 3, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Pathologic Complete Response (pCR) Rates at Time of Cystectomy
Measured over: Up to 6 months
Event-free Survival (EFS) Per Central Review Defined as Time From Randomization to Event
Measured over: Up to 48 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03732677 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC